ALX Oncology's CEO on CD47 after Gilead's magrolimab news last week, and why he believes his asset is fundamentally different

blonca9
Feb 14, 2024
1 min read

Jason Lettmann describes how he believes having an inactive Fc domain makes all the difference in the CD47 space, and he previews the clinical data we will see over the course of 2024 to help further this hypothesis.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

ALX Oncology's CEO on CD47 after Gilead's magrolimab news last week, and why he believes his asset is fundamentally different

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight